IONS Stock Recent News

–   Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif. , Oct. 3, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE).

The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.

Zilganersen is the first investigational medicine in clinical development for adults and children living with Alexander disease, an ultra-rare neurological condition CARLSBAD, Calif. , Oct. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted zilganersen Fast Track designation for the treatment of children and adults with an ultra-rare, progressive and ultimately fatal neurological disorder known as Alexander disease (AxD).

IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.

CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock.

CARLSBAD, Calif. , Aug. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events.

Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.

Ionis Pharmaceuticals specializes in RNA-targeted therapies for neurological and cardiometabolic diseases using antisense DNA technology. The company has a robust pipeline with over 40 drug candidates, developed in partnership with major pharmaceutical companies and in-house. In 2024, Ionis launched Wainua for ATTRv-PN and Qalsody for SOD1-ALS, marking significant milestones in its product portfolio.

Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2024 Earnings Conference Call August 1, 2024 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Richard Geary - Executive Vice President and Chief Development Officer Kyle Jenne - Executive Vice President and Chief Global Product Strategy Officer Elizabeth Hougen - Executive Vice President and Chief Financial Officer Eric Swayze - Executive Vice President of Research Eugene Schneider - Executive Vice President, Chief Clinical Development and Operations Officer Jonathan Birchall - Chief Commercial Officer Conference Call Participants Amy Li - Jefferies Myles Minter - William Blair Yanan Zhu - Wells Fargo Securities Jessica Fye - JPMorgan Allison Bratzel - Piper Sandler Yaron Werber - TD Cowen Jason Gerberry - Bank of America Jay Olson - Oppenheimer Michael Ulz - Morgan Stanley Gary Nachman - Raymond James Salveen Richter - Goldman Sachs Kostas Biliouris - BMO Capita